implants that will boost 2016 revenue, an improved outlook for Sapien XT and upside potential from litigation with Medtronic ( MDT ) due to its infringement of two EW US patents. EW closed Friday at $72.07. Post your comment!
who have serious cases of orgasmic dysfunction where some women's brains interpret arousal as a fear response. Medtronic ( MDT ) has signed on to conduct tests. No decision on developing a mass market version has been disclosed. 5 comments
Medtronic , Inc. ( MDT ) Cowen and Company 34th Annual Healthcare Conference Call March 05 ..... Coyle, Executive Vice President of Cardiac and Vascular Group at Medtronic . Mike thanks so much for joining and participating today. We
St. Jude remains a distant second to Medtronic in the implantable cardioverter defibrillator market ..... ICDs in the 2014-2015 time frame. Even though rival Medtronic eked out some pacemaker share gains over the last couple
pressure. For spine, we expect nearly 3% average annual declines over the next five years, as larger competitors like Medtronic and J&J reinforce their positions with next-generation products. In total, we project 4.9% average annual revenue
The world of spinal care continues to be divided among the slow-growing giants like Johnson & Johnson ( JNJ ), Medtronic ( MDT ), and Stryker ( SYK ) and the much faster-growing up-and-comers like NuVasive ( NUVA ) and Globus Medical
spinal stabilization devices) giant Medtronic ( MDT ), which reported fiscal third-quarter results February 18. Medtronic has #1 share positions in almost ..... neuro/ortho, and diabetes. Medtronic is poised to capture a nice piece
Medtronic 's MDT wide moat is rooted in its dominant presence ..... historical stronghold in heart disease. Medtronic 's moat comes from several sources. First, in the cardiac area, Medtronic benefits from efficient scale, with
By Trefis : Medical device maker Medtronic ( MDT ) reported year-over-year ..... to new product launches. When Medtronic comes out with its Q3 fiscal 2014 ..... margins to remain stable near 74% as Medtronic 's cost saving efforts under its
Feb 18 (Reuters) - Medtronic Inc on Tuesday reported a lower quarterly net profit after it took charges for a blood pressure-lowering device that failed to prove effective in a major clinical study.